Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

Circulation 2022; online ahead of print DOI: 10.1161/CIRCULATIONAHA.122.060511

Iron deficiency is common in heart failure (HF), possibly due to reduced dietary intake, gut oedema, or medication use, which may inhibit both iron absorption and use. This study examined the prevalence and consequences of iron deficiency in the DAPA-HF trial, and the effect of dapagliflozin on markers of iron metabolism, using data from over 3,000 patients.

The finding of a consistent benefit by iron status at baseline suggests that pre-existing deficiency should not be considered as a barrier to the initiation of dapagliflozin – or development of deficiency during treatment as a reason to discontinue.